Mounjaro®
Starting from £179.99/mo
Start journey Learn moreDizziness on Mounjaro is common, particularly in the first few weeks or after a dose step-up, and there are several straightforward things you can do to reduce it. Most people find it settles as their body adjusts. The underlying reasons range from reduced appetite affecting fluid and salt intake to the medicine slowing gastric emptying and influencing blood pressure. Tirzepatide is a prescription-only medicine; a prescriber assesses whether it is right for you, and any persistent or severe dizziness should always be discussed with your clinical team rather than managed alone. You can read a broader overview of dizziness as a side effect of Mounjaro if you want the full picture before diving into solutions.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Understanding the cause makes the remedy easier to apply. Tirzepatide slows gastric emptying and suppresses appetite, which together mean many people eat and drink less than usual without fully realising it. Reduced fluid intake leads to lower blood volume, and lower blood volume makes a drop in blood pressure more likely, especially when you stand up quickly. That lightheaded, slightly swimmy feeling is often the body's way of registering that signal.
There is a second mechanism worth knowing about. Because tirzepatide also affects how the body handles blood sugar, some people experience mild dips in glucose even without diabetes, particularly if they are not eating much. The result can feel similar to dehydration dizziness but has a slightly different quality: shakiness, difficulty concentrating, sudden fatigue alongside the head-spinning sensation.
The NHS medicines guidance on tirzepatide lists dizziness among the recognised side effects, noting it is more frequent during the adjustment period after starting or increasing a dose. The good news is that both causes are addressable, the steps below tackle the fluid and blood-pressure route directly, while the eating-pattern points help keep glucose steadier. If your dizziness sits alongside severe stomach pain that radiates to your back, that is a different matter entirely and needs urgent medical attention rather than home management.
The most effective first move is to sit or lie down immediately. Trying to push through dizziness while standing is how falls happen, and that risk is worth taking seriously. Once settled, drink something: plain water is fine; an electrolyte drink or diluted fruit juice is useful if you suspect you have been eating very little.
For the longer term, consistent hydration is the single change most people find most helpful. Aim to drink steadily throughout the day rather than in large gulps; keeping a bottle near wherever you store your pen acts as a natural reminder. If you keep your Mounjaro pen in the fridge door, put a water bottle on the same shelf, a small cue that links the medicine to the habit.
Salt intake matters more than many people expect on a reduced appetite. Cutting food intake significantly also cuts dietary sodium, which compounds blood-volume reduction. You do not need to add a lot, a small extra pinch on meals, or a warm broth in the evening, can make a measurable difference within a day or two. Eating something before or with your dose, even if your appetite is low, helps stabilise both blood pressure and glucose levels during the adjustment window.
Move position slowly. Sitting on the edge of the bed for a few seconds before standing, or pausing before leaving a chair, gives the blood vessels time to compensate. This is the single most practical tip for the specific pattern of dizziness that comes on with position changes. For a detailed look at that pattern and how to handle it, our page on dizziness when standing on Mounjaro covers the physiology and fixes in more detail.
Yes, in two ways. First, the days immediately after your weekly injection tend to be when the medicine's concentration in your system peaks, usually 24 to 72 hours post-injection. Scheduling your dose for a day when you can take things a little steadier can help: evenings work well for some people because any peak-effect dizziness arrives during sleep. Others prefer mornings when they know they will be sitting down to work.
Second, each dose increase resets the adjustment clock. Stepping from 2.5 mg to 5 mg, or from 5 mg to 7.5 mg, often brings a brief return of side effects that had faded. That is entirely expected; the body needs time to recalibrate at each new level. Dose titration is always a prescriber decision, the schedule in the product information leaflet and your personal clinical history both factor into when stepping up is appropriate. What you can do is be a little more attentive to fluids and position changes in the first week after any increase.
The broader story of how tirzepatide works as a dual GIP and GLP-1 receptor agonist is covered on our tirzepatide mechanism page if you want to understand why these side effects occur at a physiological level, and if you are thinking about ending treatment, our guide on how to stop tirzepatide walks through the steps to do so carefully. And if you are weighing up whether treatment is the right route at all, our treatment overview explains the full clinical process from consultation onward.
Most dizziness on Mounjaro is mild, positional and self-limiting. There are, however, patterns that need prompt attention. Contact your prescriber or NHS 111 if dizziness is severe enough to stop you functioning, does not ease after resting and rehydrating, is accompanied by chest pain, shortness of breath or a very fast or irregular heartbeat, or if you faint. These could point to a significant blood pressure drop or another cause unrelated to tirzepatide.
A sustained dizziness that does not improve over two to three weeks of consistent hydration and pacing efforts is worth raising at your next clinical review rather than waiting. It may indicate that your current dose is not the right fit, or that something else needs investigating.
Unexpected or unusual symptoms on any GLP-1 medicine can be reported to the MHRA via the Yellow Card scheme, this supports ongoing safety monitoring for medicines still under active surveillance, and tirzepatide carries a Black Triangle (▼) status for that reason. The NHS tirzepatide medicines page lists all recognised side effects and their typical severity, which is a reliable first reference before deciding whether to seek urgent help or wait and monitor.
If you are considering stopping Mounjaro because dizziness is affecting your quality of life, do not do so abruptly without speaking to your prescriber first, and our dedicated page on how to stop using Mounjaro covers what to discuss before making that decision. Our page on stopping Mounjaro safely covers what to discuss before making that decision. And if you have questions about your care between reviews, you can always reach our aftercare team, we are available seven days a week.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.